Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive

May 12, 2026 8:01 AM

Daré Bioscience Inc. (NASDAQ: DARE) announced interim results from its Phase 3 clinical trial of Ovaprene, an investigational monthly hormone-free ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found